Cogentix Medical (NASDAQ: CGNT) said today that Medicare Administrative Contractor Palmetto GBA extended granted coverage for percutaneous tibial nerve stimulation procedures to treat overactive bladder with the company’s PC Neuromod System.
With the extension, patients with Medicare coverage in North Carolina, South Carolina, parts of Virginia and West Virginia will be eligible to receive PTNS therapy for up to 3 years, adding an additional year onto previous coverage, the Minneapolis, Minn.-based company said.
“On behalf of the many overactive bladder patients who can benefit from Urgent PC’s therapeutic benefits, we applaud Palmetto’s decision to extend its coverage policy for PTNS maintenance treatments from two to three years. We believe this update underscores the value of Urgent PC as a long-term treatment option for an indication that has substantial unmet clinical need,” prez & CEO Darin Hammers said in a press release.
“Our office and, more importantly, our patients, were very excited regarding the recent decision by Palmetto to extend their coverage for PTNS. PTNS is a very important therapy for overactive bladder and it plays an integral role in helping us deliver excellence to our patients,” urologist Dr. Scott MacDiarmid of Greensboro, NC said in a prepared statement.
In July, Cogentix said it acquired London-based Genesis Medical for an undisclosed amount.